# Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

> **NCT01986920** · PHASE1,PHASE2 · COMPLETED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Seborrheic Keratosis (SK)

## Interventions

- **DRUG:** A-101 25%
- **DRUG:** A-101 32.5%
- **DRUG:** A-101 40%
- **DRUG:** A-101 Vehicle

## Key facts

- **NCT ID:** NCT01986920
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-22
- **Primary completion:** 2014-02-25
- **Final completion:** 2014-02-25
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2018-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986920, "Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01986920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*